MAPT and Alzheimer disease: The reductions of tTau and p181tau in the AD participants and not healthy participants may be due to a higher percentage of total tau species being phosphorylated at the p217 epitope in AD participants (8.5%) (31) as compared with healthy participants (1.9%) (30).